APA (7th ed.) Citation

Schneeweiss, A., Michel, L. L., Möbus, V., Tesch, H., Klare, P., Hahnen, E., . . . Loibl, S. (2022). Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. European journal of cancer, 160, . https://doi.org/10.1016/j.ejca.2021.10.011

Chicago Style (17th ed.) Citation

Schneeweiss, Andreas, et al. "Survival Analysis of the Randomised Phase III GeparOcto Trial Comparing Neoadjuvant Chemotherapy of Intense Dose-dense Epirubicin, Paclitaxel, Cyclophosphamide Versus Weekly Paclitaxel, Liposomal Doxorubicin (plus Carboplatin in Triple-negative Breast Cancer) for Patients with High-risk Early Breast Cancer." European Journal of Cancer 160 (2022). https://doi.org/10.1016/j.ejca.2021.10.011.

MLA (9th ed.) Citation

Schneeweiss, Andreas, et al. "Survival Analysis of the Randomised Phase III GeparOcto Trial Comparing Neoadjuvant Chemotherapy of Intense Dose-dense Epirubicin, Paclitaxel, Cyclophosphamide Versus Weekly Paclitaxel, Liposomal Doxorubicin (plus Carboplatin in Triple-negative Breast Cancer) for Patients with High-risk Early Breast Cancer." European Journal of Cancer, vol. 160, 2022, https://doi.org/10.1016/j.ejca.2021.10.011.